Efficacy and Safety Analysis of Tirizizumab Assisted Platinum Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
Objective To investigate the efficacy and safety of tirelizumab assisted platinum chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Eighty-Three patients with advanced NSCLC admitted to Ju County People's Hospital from February 2021 to July 2023 were selected as the study objects,and were divided into an observation group (n=42) and a control group (n=41) according to random number table method. The control group was treated with platinum chemotherapy,and the observation group was treated with tirellizumab on this basis of the control group. Both groups were treated continuously for 3 cycles. The clinical efficacy,the levels of tumor markers and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 71.43％,which was higher than 48.78％ of the control group,and the difference was statistically significant (P<0.05). After treatment,the levels of carcinoembryonic antigen,carbohydrate antigen 125,cytokeratin 19 fragment and squamous cell carcinoma antigen in the observation group were (10.69±1.52)mg/mL,(41.54±3.49)U/mL,(4.89±1.05)mg/mL and (20.14±1.55)mg/mL,respectively,which were lower than (17.14±1.87)mg/mL,(53.69±4.21)U/mL,(7.17±1.32)mg/mL,(29.87±2.96)mg/mL in the control group,and the differences between the groups were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The use of tirelizumab assisted platinum chemotherapy in the treatment of advanced NSCLC can effectively improve the levels of tumor markers in patients and will not increase the occurrence of adverse drug reactions,with high safety and significant clinical effects.
NETL
NSTL
万方数据
